283 related articles for article (PubMed ID: 35676188)
61. Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer.
Ochi T; Bianchini G; Ando M; Nozaki F; Kobayashi D; Criscitiello C; Curigliano G; Iwamoto T; Niikura N; Takei H; Yoshida A; Takei J; Suzuki K; Yamauchi H; Hayashi N
Eur J Cancer; 2019 Sep; 118():41-48. PubMed ID: 31302586
[TBL] [Abstract][Full Text] [Related]
62. Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017.
De Los Santos JF; Cantor A; Amos KD; Forero A; Golshan M; Horton JK; Hudis CA; Hylton NM; McGuire K; Meric-Bernstam F; Meszoely IM; Nanda R; Hwang ES
Cancer; 2013 May; 119(10):1776-83. PubMed ID: 23436342
[TBL] [Abstract][Full Text] [Related]
63. Prognostic value of p53 expression in hormone receptor-positive and human epidermal growth factor receptor 2-negative breast cancer patients receiving neoadjuvant chemotherapy.
Albinsaad LS; Kim J; Chung IY; Ko BS; Kim HJ; Lee JW; Son BH; Ahn SH; Lee SB
Breast Cancer Res Treat; 2021 Jun; 187(2):447-454. PubMed ID: 33599867
[TBL] [Abstract][Full Text] [Related]
64. Can Routine Imaging After Neoadjuvant Chemotherapy in Breast Cancer Predict Pathologic Complete Response?
Schaefgen B; Mati M; Sinn HP; Golatta M; Stieber A; Rauch G; Hennigs A; Richter H; Domschke C; Schuetz F; Sohn C; Schneeweiss A; Heil J
Ann Surg Oncol; 2016 Mar; 23(3):789-95. PubMed ID: 26467456
[TBL] [Abstract][Full Text] [Related]
65. Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer.
Miglietta F; Dieci MV; Tsvetkova V; Griguolo G; Vernaci G; Menichetti A; Faggioni G; Giarratano T; Mioranza E; Genovesi E; Cumerlato E; Bottosso M; Saibene T; Michieletto S; Lo Mele M; Conte P; Guarneri V
Oncologist; 2020 Sep; 25(9):e1355-e1362. PubMed ID: 32618068
[TBL] [Abstract][Full Text] [Related]
66. Phase II trial of eribulin in patients who do not achieve pathologic complete response (pCR) following neoadjuvant chemotherapy.
Yardley DA; Peacock N; Daniel B; Anz B; Molthrop DC; Shroff SK; Young R; Jankov A; Vander Woude A; Shastry M; Pasek J; DeBusk LM; Hainsworth JD
Breast Cancer Res Treat; 2020 Apr; 180(3):647-655. PubMed ID: 32060783
[TBL] [Abstract][Full Text] [Related]
67. Characterizing Occult Nodal Disease Within a Clinically Node-Negative, Neoadjuvant Breast Cancer Population.
Hammond JB; Scott DW; Kosiorek HE; Parnall TH; Gray RJ; Ernst BJ; Northfelt DW; McCullough AE; Ocal IT; Pockaj BA; Cronin PA
Clin Breast Cancer; 2022 Feb; 22(2):186-190. PubMed ID: 34462208
[TBL] [Abstract][Full Text] [Related]
68. The Landmark Series: Neoadjuvant Chemotherapy for Triple-Negative and HER2-Positive Breast Cancer.
Leon-Ferre RA; Hieken TJ; Boughey JC
Ann Surg Oncol; 2021 Apr; 28(4):2111-2119. PubMed ID: 33486641
[TBL] [Abstract][Full Text] [Related]
69. Accuracy of morphologic change measurements by ultrasound in predicting pathological response to neoadjuvant chemotherapy in triple-negative and HER2-positive breast cancer.
Ochi T; Tsunoda H; Matsuda N; Nozaki F; Suzuki K; Takei H; Yamauchi H
Breast Cancer; 2021 Jul; 28(4):838-847. PubMed ID: 33560514
[TBL] [Abstract][Full Text] [Related]
70. Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti-PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast Cancer.
Gonzalez-Ericsson PI; Wulfkhule JD; Gallagher RI; Sun X; Axelrod ML; Sheng Q; Luo N; Gomez H; Sanchez V; Sanders M; Pusztai L; Petricoin E; Blenman KRM; Balko JM;
Clin Cancer Res; 2021 Oct; 27(19):5299-5306. PubMed ID: 34315723
[TBL] [Abstract][Full Text] [Related]
71. Common and discriminative clinicopathological features between breast cancers with pathological complete response or progressive disease in response to neoadjuvant chemotherapy.
Osako T; Horii R; Matsuura M; Ogiya A; Domoto K; Miyagi Y; Takahashi S; Ito Y; Iwase T; Akiyama F
J Cancer Res Clin Oncol; 2010 Feb; 136(2):233-41. PubMed ID: 19685074
[TBL] [Abstract][Full Text] [Related]
72. Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy.
Darb-Esfahani S; Loibl S; Müller BM; Roller M; Denkert C; Komor M; Schlüns K; Blohmer JU; Budczies J; Gerber B; Noske A; du Bois A; Weichert W; Jackisch C; Dietel M; Richter K; Kaufmann M; von Minckwitz G
Breast Cancer Res; 2009; 11(5):R69. PubMed ID: 19758440
[TBL] [Abstract][Full Text] [Related]
73. Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer.
Huober J; Holmes E; Baselga J; de Azambuja E; Untch M; Fumagalli D; Sarp S; Lang I; Smith I; Boyle F; Xu B; Lecocq C; Wildiers H; Jouannaud C; Hackman J; Dasappa L; Ciruelos E; Toral Pena JC; Adamchuk H; Hickish T; de la Pena L; Jackisch C; Gelber RD; Piccart-Gebhart M; Di Cosimo S
Eur J Cancer; 2019 Sep; 118():169-177. PubMed ID: 31377477
[TBL] [Abstract][Full Text] [Related]
74. A Predictive Model for Axillary Node Pathologic Complete Response after Neoadjuvant Chemotherapy for Breast Cancer.
Kantor O; Sipsy LM; Yao K; James TA
Ann Surg Oncol; 2018 May; 25(5):1304-1311. PubMed ID: 29368152
[TBL] [Abstract][Full Text] [Related]
75. Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status.
Giacchetti S; Hamy AS; Delaloge S; Brain E; Berger F; Sigal-Zafrani B; Mathieu MC; Bertheau P; Guinebretière JM; Saghatchian M; Lerebours F; Mazouni C; Tembo O; Espié M; Reyal F; Marty M; Asselain B; Pierga JY
Eur J Cancer; 2017 Apr; 75():323-332. PubMed ID: 28279941
[TBL] [Abstract][Full Text] [Related]
76. The Effect of Age on Outcomes After Neoadjuvant Chemotherapy for Breast Cancer.
Verdial FC; Mamtani A; Pawloski KR; Sevilimedu V; D'Alfonso TM; Zhang H; Gemignani ML; Barrio AV; Morrow M; Tadros AB
Ann Surg Oncol; 2022 Jun; 29(6):3810-3819. PubMed ID: 35246810
[TBL] [Abstract][Full Text] [Related]
77. Is Multifocal Regression a Risk Factor for Ipsilateral Breast Tumor Recurrence in the Modern Era After Neoadjuvant Chemotherapy and Breast Conservation Therapy?
Ling DC; Sutera PA; Iarrobino NA; Diego EJ; Soran A; Johnson RR; Bhargava R; Champ CE; Beriwal S
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(4):869-876. PubMed ID: 30885777
[TBL] [Abstract][Full Text] [Related]
78. Tumor Biology and Response to Chemotherapy Impact Breast Cancer-specific Survival in Node-positive Breast Cancer Patients Treated With Neoadjuvant Chemotherapy: Long-term Follow-up From ACOSOG Z1071 (Alliance).
Boughey JC; Ballman KV; McCall LM; Mittendorf EA; Symmans WF; Julian TB; Byrd D; Hunt KK
Ann Surg; 2017 Oct; 266(4):667-676. PubMed ID: 28657941
[TBL] [Abstract][Full Text] [Related]
79. Prognostic significance of estrogen, progesterone and HER2 receptors' status conversion following neoadjuvant chemotherapy in patients with locally advanced breast cancer: Results from a tertiary Cancer Center in Saudi Arabia.
Al-Saleh K; Salah T; Arafah M; Husain S; Al-Rikabi A; Abd El-Aziz N
PLoS One; 2021; 16(3):e0247802. PubMed ID: 33667252
[TBL] [Abstract][Full Text] [Related]
80. Triple-Positive Breast Carcinoma: Histopathologic Features and Response to Neoadjuvant Chemotherapy.
Zeng J; Edelweiss M; Ross DS; Xu B; Moo TA; Brogi E; D'Alfonso TM
Arch Pathol Lab Med; 2021 Jun; 145(6):728-735. PubMed ID: 33112958
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]